Milrinone Versus Placebo in Patients With Septic Shock
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Sepsis is one of the most serious healthcare problems, worldwide, and financial burdens.
The overall mortality of severe sepsis/septic shock was 44.5-52.6%. A common cause of death
is refractory shock and multi-organ failure. Myocardial dysfunction is a relatively common
complication of septic shock. This causes a decrease in the amount of cardiac output,
resulting in insufficient blood supply to the organ and multi-organ failure and lead to death
Early goal-directed therapy began to use dobutamine in patients with septic shock Sepsis
Survival Campaign Guideline 2016 recommended drug is dobutamine and an alternative drug is
milrinone in septic shock patients with clinical signs of poor tissue perfusion.